ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

DCT Board Insists On Being Heard In Development Of CCOP Guidelines

February 19, 1982

Avastin Loses Indication for Breast Cancer

November 18, 2011

NCI Funding Plan For 1983: 20% Cut From Recommended Levels for All Grants, Change In Program Projects

October 8, 1982

SWOG Phase III Trial To Test Treatment For Inoperable, Locally Advanced NSCLC

September 28, 2001

Interview with Claudia Henschke: Observational Study Of Spiral CT Should Change Medical Practice, She Says.

November 3, 2006

Zerhouni Appoints Two Institute Directors

September 13, 2002